Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00182767 · ClinicalTrials.gov registry record · Phase 1
Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
NCT00182767: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00182767 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 45 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00182767, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
Study Summary
This trial is studying the side effects and best dose of ixabepilone when given together with pegylated liposomal doxorubicin hydrochloride and to see how well they work in treating women with advanced ovarian epithelial, primary peritoneal cavity, or fallopian tube cancer or metastatic breast cancer. Drugs used in chemotherapy, such as ixabepilone and pegylated liposomal doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.
Interventions
- DRUG pegylated liposomal doxorubicin hydrochloride
- DRUG ixabepilone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2006-01 |
| Est. Completion | 2014-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00182767
The ClinicalTrials.gov registry entry for NCT00182767 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which pegylated liposomal doxorubicin hydrochloride is the first listed.
NCT00182767 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00182767 about?
NCT00182767 is a clinical study titled "Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer". This trial is studying the side effects and best dose of ixabepilone when given together with pegylated liposomal doxorubicin hydrochloride and to see how well they work in treating women with advanced ovarian epithelial, primary peritoneal cavity, or fallopian tube cancer or metastatic breast cance...
What is the current status of trial NCT00182767?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2006-01. Estimated completion is 2014-05.
What interventions are being tested in trial NCT00182767?
The interventions under investigation include: pegylated liposomal doxorubicin hydrochloride (DRUG), ixabepilone (DRUG).
Who is sponsoring clinical trial NCT00182767?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.